The University of Chicago Header Logo

Connection

Walter M. Stadler to Kidney Neoplasms

Back to Details
This is a "connection" page, showing publications Walter M. Stadler has written about Kidney Neoplasms.
Walter M. Stadler
Connection Strength
14.344
Kidney Neoplasms
  1. Evaluation of Provider Preferences in First-Line Metastatic Renal Cell Carcinoma: Comparison Between Dual Immunotherapy vs. Immunotherapy/Tyrosine Kinase Inhibitors. Clin Genitourin Cancer. 2022 Dec; 20(6):510-514.
    View in: PubMed
    Score: 0.572
  2. Emerging targets in kidney cancer: opportunities for drug development. Clin Adv Hematol Oncol. 2022 05; 20(5):299-300.
    View in: PubMed
    Score: 0.568
  3. Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Pharmacodynamic Biomarker for Pazopanib in Metastatic Renal Carcinoma. Clin Genitourin Cancer. 2017 04; 15(2):207-212.
    View in: PubMed
    Score: 0.382
  4. Maturing of renal cancer therapeutics. J Clin Oncol. 2014 Mar 10; 32(8):722-4.
    View in: PubMed
    Score: 0.321
  5. Predictive markers in advanced renal cell carcinoma. Semin Oncol. 2013 Aug; 40(4):459-64.
    View in: PubMed
    Score: 0.310
  6. FDG-PET as a predictive biomarker for therapy with everolimus in metastatic renal cell cancer. Cancer Med. 2013 Aug; 2(4):545-52.
    View in: PubMed
    Score: 0.308
  7. Renal cancer therapeutics: now what? Oncology (Williston Park). 2012 Mar; 26(3):301, 304.
    View in: PubMed
    Score: 0.281
  8. A phase II trial of gemcitabine, capecitabine, and bevacizumab in metastatic renal carcinoma. Am J Clin Oncol. 2011 Apr; 34(2):150-4.
    View in: PubMed
    Score: 0.263
  9. Pazopanib in renal cell carcinoma. Clin Cancer Res. 2010 Dec 15; 16(24):5923-7.
    View in: PubMed
    Score: 0.256
  10. Bevacizumab and everolimus in renal cancer: a rational way forward. J Clin Oncol. 2010 Nov 20; 28(33):e692-3; author reply e694.
    View in: PubMed
    Score: 0.255
  11. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer. 2010 Mar 01; 116(5):1272-80.
    View in: PubMed
    Score: 0.244
  12. Effective therapy for metastatic renal cancer, whither to now. J Clin Oncol. 2009 Aug 01; 27(22):3573-4.
    View in: PubMed
    Score: 0.232
  13. Vascular endothelial growth factor pathway-targeted therapy as initial systemic treatment of patients with renal cancer. Clin Genitourin Cancer. 2008 Dec; 6 Suppl 1:S22-8.
    View in: PubMed
    Score: 0.224
  14. Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J Clin Oncol. 2008 Oct 01; 26(28):4572-8.
    View in: PubMed
    Score: 0.222
  15. Angiogenesis inhibition in non-clear cell renal cancer. Clin Adv Hematol Oncol. 2008 Jul; 6(7):507-9.
    View in: PubMed
    Score: 0.218
  16. A University of Chicago consortium phase II trial of SB-715992 in advanced renal cell cancer. Clin Genitourin Cancer. 2008 Mar; 6(1):21-4.
    View in: PubMed
    Score: 0.213
  17. Multiple reference tissue method for contrast agent arterial input function estimation. Magn Reson Med. 2007 Dec; 58(6):1266-75.
    View in: PubMed
    Score: 0.209
  18. A Phase I/II study of GTI-2040 and capecitabine in patients with renal cell carcinoma. Cancer Chemother Pharmacol. 2008 Apr; 61(4):689-94.
    View in: PubMed
    Score: 0.202
  19. Prognostic factors in localized renal cell cancer. BJU Int. 2007 May; 99(5 Pt B):1212-6.
    View in: PubMed
    Score: 0.201
  20. A phase II study of ixabepilone (BMS-247550) in metastatic renal-cell carcinoma. Cancer Biol Ther. 2007 Apr; 6(4):490-3.
    View in: PubMed
    Score: 0.200
  21. Chromosomes, hypoxia, angiogenesis, and trial design: a brief history of renal cancer drug development. Clin Cancer Res. 2007 Mar 15; 13(6):1630-3.
    View in: PubMed
    Score: 0.199
  22. Sorafenib. Curr Opin Oncol. 2006 Nov; 18(6):615-21.
    View in: PubMed
    Score: 0.194
  23. A phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008. Cancer. 2006 Sep 15; 107(6):1273-9.
    View in: PubMed
    Score: 0.192
  24. A phase II study of depsipeptide in refractory metastatic renal cell cancer. Clin Genitourin Cancer. 2006 Jun; 5(1):57-60.
    View in: PubMed
    Score: 0.188
  25. New therapeutic options for renal cell carcinoma. Clin Adv Hematol Oncol. 2006 Jun; 4(6):429-30.
    View in: PubMed
    Score: 0.188
  26. Combination therapy of imatinib mesylate and interferon-alpha demonstrates minimal activity and significant toxicity in metastatic renal cell carcinoma: results of a single- institution phase II trial. Clin Genitourin Cancer. 2006 Mar; 4(4):275-80.
    View in: PubMed
    Score: 0.185
  27. Targeted agents for the treatment of advanced renal cell carcinoma. Cancer. 2005 Dec 01; 104(11):2323-33.
    View in: PubMed
    Score: 0.182
  28. Novel kinase inhibitors in renal cell carcinoma: progressive development of static agents. Curr Oncol Rep. 2005 Mar; 7(2):116-22.
    View in: PubMed
    Score: 0.173
  29. Therapeutic options for variant renal cancer: a true orphan disease. Clin Cancer Res. 2004 Sep 15; 10(18 Pt 2):6393S-6S.
    View in: PubMed
    Score: 0.167
  30. Cytotoxic chemotherapy for metastatic renal cell carcinoma. Urologe A. 2004 Sep; 43 Suppl 3:S145-6.
    View in: PubMed
    Score: 0.167
  31. Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study. J Clin Oncol. 2004 Jan 01; 22(1):115-9.
    View in: PubMed
    Score: 0.159
  32. Prognostic factors for survival with gemcitabine plus 5-fluorouracil based regimens for metastatic renal cancer. J Urol. 2003 Oct; 170(4 Pt 1):1141-5.
    View in: PubMed
    Score: 0.157
  33. The role of systemic chemotherapy in the treatment of kidney cancer. Cancer Treat Res. 2003; 116:173-82.
    View in: PubMed
    Score: 0.149
  34. A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma. Cancer. 2002 Oct 15; 95(8):1629-36.
    View in: PubMed
    Score: 0.147
  35. A phase II trial of oral temozolomide in patients with metastatic renal cell cancer. Cancer Chemother Pharmacol. 2002 Aug; 50(2):160-2.
    View in: PubMed
    Score: 0.144
  36. A phase II trial of intravenous gemcitabine and 5-fluorouracil with subcutaneous interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinoma. Cancer. 2002 May 15; 94(10):2602-9.
    View in: PubMed
    Score: 0.142
  37. Flt-3 ligand and sequential FL/interleukin-2 in patients with metastatic renal carcinoma: clinical and biologic activity. J Immunother. 2002 May-Jun; 25(3):269-77.
    View in: PubMed
    Score: 0.142
  38. NF2-mutated Renal Carcinomas Have Common Morphologic Features Which Overlap With Biphasic Hyalinizing Psammomatous Renal Cell Carcinoma: A Comprehensive Study of 14 Cases. Am J Surg Pathol. 2022 05 01; 46(5):617-627.
    View in: PubMed
    Score: 0.142
  39. Biomarker-Based Phase II Study of Sapanisertib (TAK-228): An mTORC1/2 Inhibitor in Patients With Refractory Metastatic Renal Cell Carcinoma. JCO Precis Oncol. 2022 02; 6:e2100448.
    View in: PubMed
    Score: 0.140
  40. A Prospective Multicenter Evaluation of Initial Treatment Choice in Metastatic Renal Cell Carcinoma Prior to the Immunotherapy Era: The MaRCC Registry Experience. Clin Genitourin Cancer. 2022 02; 20(1):1-10.
    View in: PubMed
    Score: 0.134
  41. Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC). Cancer. 2021 07 01; 127(13):2204-2212.
    View in: PubMed
    Score: 0.132
  42. Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial. Eur Urol. 2021 05; 79(5):665-673.
    View in: PubMed
    Score: 0.131
  43. Angiokines Associated with Targeted Therapy Outcomes in Patients with Non-Clear Cell Renal Cell Carcinoma. Clin Cancer Res. 2021 06 15; 27(12):3317-3328.
    View in: PubMed
    Score: 0.131
  44. Eosinophilic renal cell carcinoma with isolated MTOR mutation metastatic to the liver: a novel case. Pathology. 2021 Oct; 53(6):790-793.
    View in: PubMed
    Score: 0.130
  45. Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer. J Clin Oncol. 2000 Jun; 18(12):2419-26.
    View in: PubMed
    Score: 0.124
  46. Granulocyte-macrophage-colony stimulating factor in combination immunotherapy for patients with metastatic renal cell carcinoma: results of two phase II clinical trials. Cancer. 2000 Mar 15; 88(6):1317-24.
    View in: PubMed
    Score: 0.123
  47. Patient-Reported Outcomes from the Phase III Randomized IMmotion151 Trial: Atezolizumab + Bevacizumab versus Sunitinib in Treatment-Naïve Metastatic Renal Cell Carcinoma. Clin Cancer Res. 2020 06 01; 26(11):2506-2514.
    View in: PubMed
    Score: 0.122
  48. Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium study. J Clin Oncol. 2000 Jan; 18(2):371-5.
    View in: PubMed
    Score: 0.121
  49. Renal cancer immunotherapy: a ray of hope or regression to the mean? Cancer Invest. 2000; 18(5):490-1.
    View in: PubMed
    Score: 0.121
  50. Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal carcinoma. J Clin Oncol. 1999 Aug; 17(8):2541-5.
    View in: PubMed
    Score: 0.117
  51. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet. 2019 06 15; 393(10189):2404-2415.
    View in: PubMed
    Score: 0.115
  52. The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER? Future Oncol. 2019 May; 15(15):1683-1695.
    View in: PubMed
    Score: 0.115
  53. Complete response of renal cell carcinoma vena cava tumor thrombus to neoadjuvant immunotherapy. J Immunother Cancer. 2019 03 11; 7(1):66.
    View in: PubMed
    Score: 0.114
  54. Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study. Lancet Oncol. 2019 04; 20(4):581-590.
    View in: PubMed
    Score: 0.114
  55. Kidney cancer. Lancet. 1998 Nov 21; 352(9141):1691-6.
    View in: PubMed
    Score: 0.112
  56. Cytokine therapy in metastatic renal cancer. N Engl J Med. 1998 Sep 17; 339(12):849; author reply 850-1.
    View in: PubMed
    Score: 0.110
  57. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat Med. 2018 06; 24(6):749-757.
    View in: PubMed
    Score: 0.108
  58. Multicenter phase II trial of interleukin-2, interferon-alpha, and 13-cis-retinoic acid in patients with metastatic renal-cell carcinoma. J Clin Oncol. 1998 May; 16(5):1820-5.
    View in: PubMed
    Score: 0.108
  59. Prognostic importance of lymphovascular invasion in urothelial carcinoma of the renal pelvis. Cancer. 2018 06 15; 124(12):2507-2514.
    View in: PubMed
    Score: 0.107
  60. Bevacizumab alone or in combination with TRC105 for patients with refractory metastatic renal cell cancer. Cancer. 2017 Dec 01; 123(23):4566-4573.
    View in: PubMed
    Score: 0.103
  61. Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma. Clin Cancer Res. 2016 Nov 15; 22(22):5461-5471.
    View in: PubMed
    Score: 0.094
  62. Effect of Renal Impairment on the Pharmacokinetics and Safety of Axitinib. Target Oncol. 2016 Apr; 11(2):229-34.
    View in: PubMed
    Score: 0.093
  63. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet. 2016 May 14; 387(10032):2008-16.
    View in: PubMed
    Score: 0.093
  64. Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. Lancet Oncol. 2016 Mar; 17(3):378-388.
    View in: PubMed
    Score: 0.092
  65. First-in-human multicenter phase I study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70. Cancer Chemother Pharmacol. 2016 Jan; 77(1):155-62.
    View in: PubMed
    Score: 0.091
  66. A phase II study of subcutaneous recombinant human interleukin-4 in metastatic renal cell carcinoma. Cancer. 1995 Nov 01; 76(9):1629-33.
    View in: PubMed
    Score: 0.090
  67. Progression-free survival: does a correlation with survival justify its role as a surrogate clinical endpoint? Cancer. 2015 Jun 01; 121(11):1906.
    View in: PubMed
    Score: 0.086
  68. Low-dose interleukin-2 in the treatment of metastatic renal-cell carcinoma. Semin Oncol. 1995 Feb; 22(1):67-73.
    View in: PubMed
    Score: 0.086
  69. A phase 2, single-arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapy. Cancer. 2014 Jun 01; 120(11):1647-55.
    View in: PubMed
    Score: 0.081
  70. Stereotactic body radiotherapy for the treatment of oligometastatic renal cell carcinoma. Am J Clin Oncol. 2013 Dec; 36(6):589-95.
    View in: PubMed
    Score: 0.079
  71. Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma. Cancer. 2014 Jan 01; 120(1):52-60.
    View in: PubMed
    Score: 0.078
  72. Human renal cancer carcinogenesis: a review of recent advances. Ann Oncol. 1993 Jun; 4(6):451-62.
    View in: PubMed
    Score: 0.077
  73. Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis. J Clin Pharmacol. 2013 May; 53(5):491-504.
    View in: PubMed
    Score: 0.076
  74. Estimation of renal cell carcinoma treatment effects from disease progression modeling. Clin Pharmacol Ther. 2013 Apr; 93(4):345-51.
    View in: PubMed
    Score: 0.074
  75. Serum interleukin-6 levels in metastatic renal cell cancer: correlation with survival but not an independent prognostic indicator. J Natl Cancer Inst. 1992 Dec 02; 84(23):1835-6.
    View in: PubMed
    Score: 0.074
  76. Resampling phase III data to assess phase II trial designs and endpoints. Clin Cancer Res. 2012 Apr 15; 18(8):2309-15.
    View in: PubMed
    Score: 0.070
  77. Continuous-infusion fluorodeoxyuridine with leucovorin and high-dose interferon: a phase II study in metastatic renal-cell cancer. Cancer Chemother Pharmacol. 1992; 31(3):213-6.
    View in: PubMed
    Score: 0.069
  78. Baseline patient-reported kidney cancer-specific symptoms as an indicator for median survival in sorafenib-refractory metastatic renal cell carcinoma. J Cancer Surviv. 2011 Sep; 5(3):255-62.
    View in: PubMed
    Score: 0.066
  79. A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma. BJU Int. 2011 Sep; 108(5):679-86.
    View in: PubMed
    Score: 0.065
  80. Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access program. Oncology. 2010; 78(5-6):340-7.
    View in: PubMed
    Score: 0.063
  81. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol. 2010 May 01; 28(13):2137-43.
    View in: PubMed
    Score: 0.061
  82. Renal medullary-like carcinoma in an adult without sickle cell hemoglobinopathy. Nat Rev Urol. 2010 Feb; 7(2):110-4.
    View in: PubMed
    Score: 0.061
  83. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol. 2009 Sep 20; 27(27):4462-8.
    View in: PubMed
    Score: 0.059
  84. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol. 2009 Jul 10; 27(20):3312-8.
    View in: PubMed
    Score: 0.058
  85. Phase II trial of carboplatin and paclitaxel in papillary renal cell carcinoma. Clin Genitourin Cancer. 2009 Jan; 7(1):39-42.
    View in: PubMed
    Score: 0.056
  86. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol. 2008 Nov 20; 26(33):5422-8.
    View in: PubMed
    Score: 0.056
  87. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol. 2008 Aug 01; 26(22):3743-8.
    View in: PubMed
    Score: 0.055
  88. Phase 2 trial of talactoferrin in previously treated patients with metastatic renal cell carcinoma. Cancer. 2008 Jul 01; 113(1):72-7.
    View in: PubMed
    Score: 0.054
  89. Identification of deregulated oncogenic pathways in renal cell carcinoma: an integrated oncogenomic approach based on gene expression profiling. Oncogene. 2007 Feb 26; 26(9):1346-50.
    View in: PubMed
    Score: 0.050
  90. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007 Jan 11; 356(2):125-34.
    View in: PubMed
    Score: 0.049
  91. Gene expression profiling in kidney cancer: combining differential expression and chromosomal and pathway analyses. Clin Genitourin Cancer. 2006 Dec; 5(3):227-31.
    View in: PubMed
    Score: 0.049
  92. Adoptive immunotherapy by allogeneic stem cell transplantation for metastatic renal cell carcinoma: a CALGB intergroup phase II study. Biol Blood Marrow Transplant. 2006 Jul; 12(7):778-85.
    View in: PubMed
    Score: 0.047
  93. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006 Jun 01; 24(16):2505-12.
    View in: PubMed
    Score: 0.047
  94. A randomized phase II trial of interleukin-2 in combination with four different doses of bryostatin-1 in patients with renal cell carcinoma. Invest New Drugs. 2006 Mar; 24(2):141-9.
    View in: PubMed
    Score: 0.046
  95. Phase II study of the efficacy and safety of oral GD0039 in patients with locally advanced or metastatic renal cell carcinoma. Invest New Drugs. 2005 Dec; 23(6):577-81.
    View in: PubMed
    Score: 0.046
  96. A molecular classification of papillary renal cell carcinoma. Cancer Res. 2005 Jul 01; 65(13):5628-37.
    View in: PubMed
    Score: 0.044
  97. Successful implementation of the randomized discontinuation trial design: an application to the study of the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma--CALGB 69901. J Clin Oncol. 2005 Jun 01; 23(16):3726-32.
    View in: PubMed
    Score: 0.044
  98. Transcriptional profiles in peripheral blood mononuclear cells prognostic of clinical outcomes in patients with advanced renal cell carcinoma. Clin Cancer Res. 2005 Feb 01; 11(3):1181-9.
    View in: PubMed
    Score: 0.043
  99. Innovations and challenges in renal cancer: consensus statement from the first international conference. Clin Cancer Res. 2004 Sep 15; 10(18 Pt 2):6277S-81S.
    View in: PubMed
    Score: 0.042
  100. Gene expression profiling of renal medullary carcinoma: potential clinical relevance. Cancer. 2004 Mar 01; 100(5):976-85.
    View in: PubMed
    Score: 0.040
  101. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol. 2004 Mar 01; 22(5):909-18.
    View in: PubMed
    Score: 0.040
  102. Disease-associated expression profiles in peripheral blood mononuclear cells from patients with advanced renal cell carcinoma. Cancer Res. 2003 Sep 15; 63(18):6069-75.
    View in: PubMed
    Score: 0.039
  103. Acute bilateral abducens paralysis due to oxaliplatin. J Natl Cancer Inst. 2003 Mar 19; 95(6):488-9.
    View in: PubMed
    Score: 0.038
  104. Randomized discontinuation design: application to cytostatic antineoplastic agents. J Clin Oncol. 2002 Nov 15; 20(22):4478-84.
    View in: PubMed
    Score: 0.037
  105. Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results. J Clin Oncol. 2002 Apr 15; 20(8):2017-24.
    View in: PubMed
    Score: 0.035
  106. Allogeneic peripheral blood stem cell transplantation for metastatic renal cell carcinoma. J Urol. 2001 Apr; 165(4):1208-9.
    View in: PubMed
    Score: 0.033
  107. A phase II trial of weekly intravenous ranpirnase (Onconase), a novel ribonuclease in patients with metastatic kidney cancer. Invest New Drugs. 2001; 19(3):255-60.
    View in: PubMed
    Score: 0.032
  108. Flavopiridol metabolism in cancer patients is associated with the occurrence of diarrhea. Clin Cancer Res. 2000 Sep; 6(9):3400-5.
    View in: PubMed
    Score: 0.032
  109. Granulocyte-macrophage--colony stimulating factor in metastatic renal cell carcinoma: a phase II trial. Cancer. 1998 Apr 01; 82(7):1352-8.
    View in: PubMed
    Score: 0.027
  110. Phase II and pharmacodynamic studies of pyrazine diazohydroxide (NSC 361456) in patients with advanced renal and colorectal cancer. Clin Cancer Res. 1998 Apr; 4(4):929-34.
    View in: PubMed
    Score: 0.027
  111. High-dose continuous intravenous infusion of interleukin-2 therapy for metastatic renal cell carcinoma: the University of Chicago experience. Urology. 1996 Feb; 47(2):194-7.
    View in: PubMed
    Score: 0.023
  112. A phase I study of sirolimus and bevacizumab in patients with advanced malignancies. Eur J Cancer. 2011 Jul; 47(10):1484-9.
    View in: PubMed
    Score: 0.016
  113. Activities and accomplishments of the cancer and leukemia group B genitourinary committee. Clin Cancer Res. 2006 Jun 01; 12(11 Pt 2):3596s-600s.
    View in: PubMed
    Score: 0.012
  114. A phase II trial of sequential chemotherapy with docetaxel and methotrexate followed by gemcitabine and cisplatin for metastatic urothelial cancer. Am J Clin Oncol. 2005 Apr; 28(2):109-13.
    View in: PubMed
    Score: 0.011
  115. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies. Cancer. 2001 Sep 15; 92(6):1567-76.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.